Advancements in molecular biology technology allowed the development of promising biomarkers, such as Peripheral blood gene expression profiling (GEP) and cell-free DNA (cfDNA), for minimally invasive characterisation of allograft rejection.
The use of circulating GEP and cfDNA may offer advantages over invasive tissue biopsy as a quantitative measure for detection of transplant rejection and immunosuppression optimisation. However, there is no standard recognition of the usage of this new technology.
The objectives of this project are –
ESOT, with the kind support from CareDx, Eurofins, and Natera will lead projects to foster awareness and education in the field of Molecular Biology Testing for Non-Invasive Diagnosis of Allograft Rejection.
Kidney
Heart & Lung
Sean Agbor-EnohRead Profile
Marisa Crespo LeiroRead Profile
Kiran KhushRead ProfileLiver
Marina BerenguerRead Profile
Eleonora De MartinRead Profile
Josh LevitskyRead Profile
Valeria MasRead ProfileThis project is possible thanks to the kind support of
Addressing the biggest challenges in transplantation takes teamwork. With an ESOT membership, you’ll continue to be a valued part of Europe’s largest network of dedicated transplant professionals, sharing ideas and collaborating to improve the science and practice of transplantation.